Research programme: arginase inhibitors - Corridor Pharmaceuticals
Alternative Names: C-122Latest Information Update: 16 Jul 2016
At a glance
- Originator Johns Hopkins University; University of Pennsylvania
- Developer Corridor Pharmaceuticals
- Class Small molecules
- Mechanism of Action Arginase inhibitors; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (PO)
- 18 Jun 2010 Immune Control has merged with Arginetix to form Corridor Pharmaceuticals
- 18 Jun 2010 Preclinical trials in Pulmonary arterial hypertension in USA (PO)